VHL and neoplasm: When selecting tumours with undetectable pVHL and at least one VHL alteration (n=67, 68.4%) and comparing this former group to tumours expressing pVHL (n=31, 31.6%), the first group exhibited better outcome both in terms of PFS (log-rank test, P=0.02) and in terms of RCC-SS (log-rank test P=0.03; Figure 3A).